Showing 1 – 20 of 319
Relevance | Newest | Oldest |
  • JAMA May 27, 2009

    Figure 1: Flow of Individuals in the SCAMP Trial

    SCAMP indicates Stepped Care for Affective Disorders and Musculoskeletal Pain.
  • Cardiovascular Disease Worldwide, 1990-2013

    Abstract Full Text
    free access
    JAMA. 2015; 314(18):1905-1905. doi: 10.1001/jama.2015.14994
  • JAMA May 23, 2007

    Figure 2: Malaria Treatment Algorithm

    *If species not yet identified is subsequently diagnosed as a non-falciparum infection, then complete treatment as per the identified species recommendations. G6PD indicates glucose-6-phosphate dehydrogenase. †Central America west of the Panama Canal, Mexico, Hispaniola, parts of China, and the Middle East. ‡All malaria-endemic countries except those listed in second footnote. §Contraindicated in pregnant women and children younger than 8 years of age. ∥Drug options for chloroquine-resistant P falciparum may also be used if chloroquine or hydroxychloroquine cannot be used.
  • JAMA January 10, 2017

    Figure 3: Projected Age-Standardized Disability-Adjusted Life-Years by Systolic Blood Pressure of at Least 110 to 115 mm Hg, by Region and Cause, 2015

    Reported data include both sexes combined.aIncludes rheumatic heart disease, hypertensive heart disease, cardiomyopathy and myocarditis, atrial fibrillation and flutter, aortic aneurysm, peripheral vascular disease, endocarditis, and other cardiovascular and circulatory diseases.
  • JAMA January 10, 2017

    Figure 2: Projected Global Disability-Adjusted Life-Years by Systolic Blood Pressure Level and Cause, 2015

    Reported data are for both sexes combined and for individuals aged 25 years and older. The boxes show the median and extend from the 25th to the 75th percentiles. The upper whiskers extend from the third quartile to the highest value within 1.5 × the IQR of the third quartile; the lower whiskers extend from the first quartile to the lowest value within 1.5 × the IQR of the first quartile. Data outside the the whisker range are plotted as open circles.aCategory includes rheumatic heart disease, hypertensive heart disease, cardiomyopathy and myocarditis, atrial fibrillation and flutter, aortic aneurysm, peripheral vascular disease, endocarditis, and other cardiovascular and circulatory diseases.
  • JAMA September 20, 2016

    Figure 2: Evolution of Disease Activity Score in 28 Joints-Erythrocyte Sedimentation Rate (DAS28-ESR) and Health Assessment Questionnaire Score in Non–Tumor-Necrosis Factor (TNF) and Second Anti-TNF Groups

    The analytic sample sizes shown at baseline in Figure 2 differ from the total number randomized because of missing data. They also differ for DAS28-ESR from the numbers included in the primary analysis (European League Against Rheumatism response) because in the primary analysis, some of the patients with missing data were considered nonresponders because they received during the follow-up a biologic agent different from the treatment initially assigned, as specified in the statistical analysis section. Constrained longitudinal data analyses were used for between-group comparisons for DAS28-ESR and HAQ. For DAS-28-ESR, the 12-week P value was .008; 24- week, P = .004; and 52-week, P = .01; for HAQ, the 12-week P value was.09; 24-week, P = .44; and 52-week, P = .75. Data markers represent the mean and error bars 95% CIs. See the Methods section for a definition of disease activity score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and range and the Health Assessment Questionnaire (HAQ) definition and score range.
  • JAMA December 3, 2014

    Figure: Example of Relationship of Risk Factors With Lifetime Benefit of Colorectal Cancer Screening With Colonoscopy

    CRC indicates colorectal cancer; RR, relative risk.aIndividuals are classified as having moderate comorbidity if diagnosed with an ulcer, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, or cerebrovascular disease and in case of a history of acute myocardial infarction; as having severe comorbidity if diagnosed with chronic obstructive pulmonary disease, congestive heart failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS; and as having no comorbidity if none of these conditions is present.bThe range of the background risk for CRC is based on the National Cancer Institute’s Colorectal Cancer Risk Assessment Tool. In white women, the minimum background risk for CRC is 0.5, the maximum background risk in the absence of a family history of CRC is 1.8, and the maximum risk in the presence of a family history of CRC is 3.5.
  • Topical Nonsteroidal Anti-inflammatory Drugs for Acute Musculoskeletal Pain

    Abstract Full Text
    JAMA. 2016; 315(8):813-814. doi: 10.1001/jama.2016.0249

    This Clinical Evidence Synopsis summarizes a Cochrane review on the efficacy of topical nonsteroidal anti-inflammatory drugs to treat musculoskeletal conditions, such as sprains, strains, and contusions.

  • From JAMA ’s Daily News Site

    Abstract Full Text
    JAMA. 2014; 311(1):18-18. doi: 10.1001/jama.2013.285149
  • Rare Neurological Condition Linked to Newer Monoclonal Antibody Biologics

    Abstract Full Text
    JAMA. 2009; 301(14):1423-1424. doi: 10.1001/jama.2009.451
  • US Spending on Personal Health Care and Public Health, 1996-2013

    Abstract Full Text
    free access has multimedia
    JAMA. 2016; 316(24):2627-2646. doi: 10.1001/jama.2016.16885

    This study used data from National Health Expenditure Accounts to estimate US spending on personal health care and public health, according to condition, age and sex group, and type of care.

  • Cardiovascular Mortality Differences—Place Matters

    Abstract Full Text
    JAMA. 2017; 317(19):1955-1957. doi: 10.1001/jama.2017.4168
  • JAMA April 28, 2015

    Figure 4: Correlation Between Odds Ratios (ORs) for Susceptibility to Rheumatoid Arthritis (RA) and ORs for Treatment Response in BRAGGSS Cohort

    Treatment response correlates with susceptibility in this Figure. Horizontal and vertical error bars indicate 95% CIs. The orange line was fitted by linear regression. Haplotype groups are defined in Figure 3. The OR for a haplotype group for the association with RA susceptibility has been calculated as the weighted average of the OR of the individual haplotypes belonging to the group; haplotype frequency was used as the weight. The OR for the association with treatment response has been calculated using a multivariable ordinal logistic regression of European League Against Rheumatism response on the haplotype groups. Every patient in the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) cohort carries either 0, 1, or 2 copies of a haplotype classified as a group 1, 2, 3, or 4 haplotype. The multivariable ordinal logistic regression includes all 4 haplotype groups in the same model and the following markers of treatment response as covariates: sex, concurrent treatment with disease-modifying antirheumatic drugs, Disease Activity Score based on 28 joint counts, and Health Assessment Questionnaire disability index score at treatment initiation (baseline). The Disease Activity Score ranges from 0 to 10; a higher score indicates a higher level of disease activity. Health Assessment Questionnaire measures functional disability and ranges from 0 to 3; a higher score indicates a higher level of disability.
  • JAMA December 7, 2011

    Figure 3: Incidence Rates and Hazard Ratios for Specific TNF-α Antagonists and Serious Infections Among Patients With Rheumatoid Arthritis

    Each comparison required a separate propensity score matching iteration. TNF indicates tumor necrosis factor.
  • “Cure” of Rheumatism and Joint-Trouble

    Abstract Full Text
    JAMA. 2014; 311(3):313-313. doi: 10.1001/jama.2013.279285
  • Trends and Patterns of Geographic Variation in Cardiovascular Mortality Among US Counties, 1980-2014

    Abstract Full Text
    free access is active quiz
    JAMA. 2017; 317(19):1976-1992. doi: 10.1001/jama.2017.4150

    This population epidemiology study uses national death record and Census Bureau data to estimate trends in age-standardized cardiovascular disease mortality rates by US county between 1980 and 2014.

  • Pediatric Allergy: Principles and Practice

    Abstract Full Text
    JAMA. 2011; 306(3):320-321. doi: 10.1001/jama.2011.1007
  • Rheumatic Disease Burden

    Abstract Full Text
    JAMA. 2000; 283(14):1816-1816. doi: 10.1001/jama.283.14.1816-JWM00002-2-1
  • Risk of Adverse Fetal Outcomes Following Administration of a Pandemic Influenza A(H1N1) Vaccine During Pregnancy

    Abstract Full Text
    free access has multimedia
    JAMA. 2012; 308(2):165-174. doi: 10.1001/jama.2012.6131
    In a registry-based cohort study of all liveborn singleton infants delivered in Denmark (November 2, 2009-September 30, 2010; N= 53 432), Pasternak and coauthors assess whether prenatal exposure to adjuvanted influenza A(H1N1)pdm09 vaccine is associated with increased risk of adverse fetal outcomes.
  • Heart Valve Disorders and Appetite-Suppressant Drugs

    Abstract Full Text
    JAMA. 2000; 283(13):1738-1740. doi: 10.1001/jama.283.13.1738